Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Heplisav Vaccine Postmarketing Study Might Overcome FDA Safety Worries At Panel

Executive Summary

Dynavax has already received two complete response letters for its hepatitis B vaccine; more patients who received Heplisav died or experienced cardiovascular events compared with the competitor arm.

Advertisement

Related Content

Heplisav Postmarketing Worries Push PDUFA Date Back; FDA Seeks More Details
Heplisav Seems Headed For Approval, But With More Robust Postmarketing Study
Recent And Upcoming FDA Advisory Committee Meetings
Keeping Track: FDA Approves First Rx DHEA, Receives Applications For Midostaurin, Gesulkumab, Biosimilar Avastin
Heplisav-B Review Still On Track Even After Cancelled Advisory Cmte., Dynavax Says
Heplisav’s Hopes For U.S. Approval Could Rest On Narrower Population

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS121193

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel